Allergy Therapeutics plc (AGYTF)

USD 0.05

(0.0%)

Market Cap (In USD)

247.85 Million

Revenue (In USD)

59.58 Million

Net Income (In USD)

-43.07 Million

Avg. Volume

80.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.01-0.06
PE
-
EPS
-
Beta Value
1.347
ISIN
GB00B02LCQ05
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Manuel Llobet
Employee Count
-
Website
https://www.allergytherapeutics.com
Ipo Date
2010-02-03
Details
Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. The company also develops allergy vaccines for trees, grass, house dust mite, and pets with fur/hair, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.